Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy - PubMed
6 hours ago
- #personalized vaccine
- #extracellular vesicles
- #cancer immunotherapy
- Personalized vaccines show potential in cancer therapy by leveraging tumor-specific adaptive immunity.
- Current platforms face challenges like premature systemic clearance and imprecise antigen-presenting cell targeting.
- A tumor-derived extracellular vesicle-based scaffold vaccine is reported for personalized cancer immunotherapy.
- The vaccine forms a hydrogel reservoir for antigens and adjuvants, recruiting dendritic cells.
- Matured dendritic cells migrate to lymph nodes, inducing potent CD8+ T-cell responses.
- Patient-tailored vaccines using tumor-derived EVs show efficacy in preventing postoperative recurrence.
- The platform demonstrates robust and durable therapeutic efficacy for personalized immunotherapy.